Safety data from Avanir Pharmaceuticals’ Star trial evaluating Zenvia for treatment of pseudobulbar affect (News-Medical-Net) AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA). [News Source]